Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 137 clinical trials
Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects

Kidney transplant recipients of living- and deceased donor grafts and treated with both mycophenolate mofetil (MMF) and tacrolimus (Tac) will be included. A 12-hour pharmacokinetic (PK

renal function
immunosuppressive agents
graft loss
mycophenolate mofetil 500 mg
mycophenolate
  • 3 views
  • 05 Mar, 2021
  • 1 location
Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease

only) and graft vs. host disease (GvHD) prophylaxis consisting of post-transplant cyclophosphamide (PT-Cy), mycophenolate mofetil (MMF), and sirolimus. The investigators anticipate that this approach

vaso-occlusive crisis
cyclophosphamide
analgesia
thal
acute chest syndrome
  • 14 views
  • 25 Jan, 2021
  • 1 location
ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis

The protocols including ciclosporin A CsA+methotrexate (MTX) +mycophenolate Mofetil(MMF) have been widely used for graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem

mycophenolate mofetil
graft versus host disease
allogeneic hematopoietic stem cell transplant
methotrexate
  • 0 views
  • 23 Jan, 2021
  • 1 location
RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients

Open label, randomized, multicenter, intervention trial comparing standard immunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen in combination with

tacrolimus
immunosuppressive agents
everolimus
kidney transplant
calcineurin inhibitor
  • 5 views
  • 27 Jan, 2021
  • 7 locations
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil (PTCy/Tac/MMF) in the setting of reduced intensity conditioning (RIC) allogeneic peripheral blood stem cell (PBSC) transplantation.

bone marrow procedure
reduced intensity conditioning
cyclophosphamide
carbon monoxide
myelodysplasia
  • 1 views
  • 25 Jan, 2021
  • 35 locations
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

) following the transplant. Two drugs, cyclosporine (CSP) and sirolimus (SIR), will be combined with either mycophenolate mofetil (MMF) or post-transplant cyclophosphamide (PTCy). This part of the transplant

salvage therapy
blood stem cell transplant
recurrent disease
filgrastim
chronic myelomonocytic leukemia
  • 64 views
  • 26 Jan, 2021
  • 1 location
Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC

control of graft versus host disease after transplantation, allowing to consider stopping immunosuppressive treatment after the transplantation (Neoral=cyclosporine, cell-cept=mycophenolate mofetil

immunosuppressive agents
cyclophosphamide
cyclosporine
transplant conditioning
chronic graft versus host disease
  • 6 views
  • 05 Mar, 2021
  • 1 location
PTCy and Ruxolitinib vs PTCy Tacrolimus and MMF in MUD and Haploidentical HSCT

This is multicenter investigator-initiated randomized open-label phase II clinical trial to compare prophylaxis of graft versus host disease treated with tacrolimus and mycophenolate mofetil

  • 0 views
  • 27 Jan, 2021
  • 2 locations
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib has also been shown to inhibit dendritic cells maturation and function and possesses a number of other favorable immunomodulatory effect that can

  • 0 views
  • 26 Jan, 2021
  • 1 location
Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

reducing the immune suppression necessary to achieve optimal renal function in renal transplant recipients. All participants will receive routine care: basiliximab, tacrolimus, mycophenolate mofetil, and

tacrolimus
nephropathy
corticosteroids
induction therapy
immunosuppression
  • 25 views
  • 28 Jan, 2021
  • 1 location